Symrise AG

  • WKN: SYM999
  • ISIN: DE000SYM9999
  • Land: Deutschland

Nachricht vom 07.08.2019 | 15:56

Symrise AG: Dr Winfried Steeger - new Chairman of the Supervisory Board

Symrise AG / Key word(s): Personnel
Symrise AG: Dr Winfried Steeger - new Chairman of the Supervisory Board

07-Aug-2019 / 15:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Dr Winfried Steeger has been elected as new chairman of the supervisory board on August 7th 2019.
 
Dr Steeger is a member of the supervisory board since May 15th 2012. In addition he is also a member of the audit committee since September 20th, 2012. He has been elected as a member of the supervisory board until the end of the general meeting that decides on discharges for the 2019 fiscal year.
 
The previous chairman of the supervisory board, Dr Thomas Rabe, has decided to resign as chairman of the supervisory board with effect as of the end of the supervisory board meeting of August 7th 2019. He will remain and continue as member of the supervisory board. The resignation of Dr Rabe as chairman of the supervisory board is connected to his election as member of the supervisory board of Adidas in the general meeting of Adidas on May 9th 2019.



Contact:
Tobias Erfurth, Investor Relations

07-Aug-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG: Statement zum Artikel der Financial Times

16. Oktober 2019, 09:01

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

16. Oktober 2019